MarkGabrielLebwohlMD

Dean for Clinical Therapeutics, Professor and Chairman Emeritus of Dermatology, Icahn School of Medicine at Mount Sinai

Overview of Dr. Lebwohl

Dr. Mark Lebwohl is a dermatologist in New York, NY and is affiliated with multiple hospitals in the area, including The Mount Sinai Hospital, Mount Sinai West, Mount Sinai Morningside, Mount Sinai Beth Israel, Mount Sinai Hospital of Queens, New York Eye and Ear Infirmary of Mount Sinai, and Mount Sinai Brooklyn. He received his medical degree from Harvard Medical School and has been in practice 45 years. He is one of 52 doctors at Mount Sinai Brooklyn and one of 23 doctors at New York Eye and Ear Infirmary of Mount Sinai who specialize in Dermatology. He has more than 100 publications and over 500 citings.

Office
5 e 98 st
New York, NY 10029
Book by Phone+1(901) 621-5794

Education & Training

Icahn School of Medicine at Mount SinaiResidency, Dermatology, 1981 - 1983
Icahn School of Medicine at Mount Sinai/Mount Sinai HospitalResidency, Internal Medicine, 1978 - 1981
Harvard Medical SchoolClass of 1978

Certifications & Licensure

NY State Medical License 1980 - 2027
American Board of Dermatology Dermatology
American Board of Internal Medicine Internal Medicine

Awards, Honors, & Recognition

Gold Medal American Academy of Dermatology, 2022
Top MD Consumers Checkbook
Whos Who in Medicine and Healthcare Marquis Whos Who
Super Doctor SuperDoctors.com
Fellow (FAAD) American Academy of Dermatology
Join now to see all

Clinical Trials

LEO 80185 in the Treatment of Psoriasis Vulgaris on the Non-scalp Regions of the Body (Trunk and/or Limbs)
COMPLETED
PHASE3
Magnesium Supplements In The Treatment Of Pseudoxanthoma Elasticum (PXE) Start of enrollment: 2012 Aug 01
Completed
Phase 2
LEO 90100 in the Treatment of Psoriasis Vulgaris
COMPLETED
PHASE2
Ingenol Mebutate 0.015% Gel in the Treatment of Actinic Keratoses (AK) on the Face and Scalp Start of enrollment: 2013 Mar 01
Completed
Phase 1
Safety and Effectiveness of CNDO 201Trichuris Suis Ova (TSO) for the Treatment of Moderate to Severe Plaque Psoriasis Start of enrollment: 2013 Mar 01
Completed
Phase 1
Phase IIa Study of Multiple Doses of AbGn-168H by iv Infusion in Moderate to Severe Chronic Plaque Psoriasis Patients Start of enrollment: 2013 May 01
Completed
Phase 2
Evaluation of CL Detect™ Rapid Test to Detect Cutaneous Leishmaniasis Start of enrollment: 2013 Jun 01
Completed
Efficacy of Ustekinumab Followed by Abatacept for the Treatment of Psoriasis Vulgaris Start of enrollment: 2014 Mar 19
Completed
Phase 2
Reduction of Pain Caused by Biologic Drugs in Psoriasis Start of enrollment: 2014 May 01
Completed
Not Applicable
Addition of Excimer Laser to Treatment With Acitretin Tablets for Psoriasis of the Palms and Soles Start of enrollment: 2014 Jun 01
Terminated
Phase 4
A Study of Multiple Doses of AbGn-168H by Intravenous Infusion in Patients With Moderate to Severe Chronic Plaque Psoriasis Start of enrollment: 2014 May 01
Completed
Phase 2
Treatment of Actinic Keratoses (AK) on the Face Start of enrollment: 2015 Mar 01
Completed
Phase 1
LEO 90100 Twice Weekly Maintenance Regimen for Psoriasis Vulgaris Start of enrollment: 2017 Feb 15
Completed
Phase 3
Combined Therapy With Narrow-Band Ultraviolet B Phototherapy and Apremilast for the Treatment of Vitiligo Start of enrollment: 2017 Apr 14
Completed
Phase 2
Effisayil™ ON: A Study to Test Long-term Treatment With Spesolimab in People With Generalized Pustular Psoriasis Who Took Part in a Previous Study Start of enrollment: 2019 May 29
ACTIVE_NOT_RECRUITING
PHASE2
Join now to see all

Publications & Presentations

PubMed

Effect of spesolimab on sustained disease control in patients with generalized pustular psoriasis: Post hoc analysis of the EFFISAYIL 2 study.
Kenneth B Gordon, Matthias Augustin, Jonathan Barker, Yayoi Tada, Mark G Lebwohl
Journal of the American Academy of Dermatology. 2025-03-07
Deucravacitinib in plaque psoriasis: Four-year safety and efficacy results from the Phase 3 POETYK PSO-1, PSO-2 and long-term extension trials.
April W Armstrong, Mark Lebwohl, Richard B Warren, Howard Sofen, Akimichi Morita
Journal of the European Academy of Dermatology and Venereology. 2025-03-06
Remibrutinib in Chronic Spontaneous Urticaria.
Martin Metz, Ana Giménez-Arnau, Michihiro Hide, Mark Lebwohl, Giselle Mosnaim
The New England Journal of Medicine. 2025-03-06

Lectures

Dilemmas and Challenges in Skin Cancer Therapies and Management
American Academy of Dermatology - Annual Meeting 2019 - Washington, D.C. - 3/4/2019

Authored Content

How Dermatologists Can Address Obesity to Improve Psoriasis OutcomesMarch 2025

Press Mentions

Anti–IL-23 Therapy Might Emerge as Best Biologic in Psoriasis if Used Early and at High DosesMarch 20th, 2025
How Dermatologists Can Address Obesity to Improve Psoriasis OutcomesMarch 5th, 2025
MoonLake Initiates Three New Clinical Trials and Further Expands the Portfolio of Indications for the Nanobody® SonelokimabJanuary 9th, 2025
Join now to see all